The administration of FabiSpray, a nitric oxide nasal spray (NONS), in unvaccinated adult patients with co-morbid conditions reduced Covid-19 viral load by 93 to 97 per cent, a new study published in the Lancet Regional Health, South Asia, has demonstrated.
A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of Phase-3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.
The study on Nitric Oxide Nasal Spray (NONS) was conducted by Mumbai-based pharmaceutical company Glenmark in 306 vaccinated and unvaccinated adults with symptomatic mild Covid-19 across 20 clinical sites in India
A nasal spray administered in high-risk adult Covid patients in India reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.